Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

ClinicalTrials.gov ID: NCT05307939

Public ClinicalTrials.gov record NCT05307939. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Trial Evaluating Selective Minimal Residual Disease Directed Adjuvant Radiation in Human Papilloma Virus Associated Oropharynx Carcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will look at whether monitoring HPV ctDNA levels is an effective way to detect cancer relapse risk in people with HPV-OPC. All participants will have recently had surgery to treat their disease, or they will be scheduled to have this surgery. In Arm A the researchers will see whether monitoring participants' HPV ctDNA levels can safely identify patients who do not need radiation therapy (RT) after surgery and whose RT can be delayed until their HPV ctDNA levels become detectable. In Arm B, the researchers will see whether patients who usually need 6-6.5 weeks of CRT can be selected by HPV ctDNA to receive 3 weeks of CRT.

Study identification

NCT ID
NCT05307939
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Enrollment
30 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 23, 2022
Primary completion
Mar 23, 2027
Completion
Mar 23, 2027
Last update posted
Apr 12, 2026

2022 – 2027

United States locations

U.S. sites
8
U.S. states
3
U.S. cities
8
Facility City State ZIP Site status
Baptist Alliance MCI (Data Collection Only) Miami Florida 33143 Recruiting
Memorial Sloan Kettering Basking Ridge (Limited protocol activities) Basking Ridge New Jersey 07920 Recruiting
Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown New Jersey 07748 Recruiting
Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale New Jersey 07645 Recruiting
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) Commack New York 11725 Recruiting
Memorial Sloan Kettering Westchester (Limited Protocol Activites) East White Plains New York 10604 Recruiting
Memorial Sloan Kettering Cancer Center (All Protocol Activities) New York New York 10065 Recruiting
Memorial Sloan Kettering Nassau (Limited protocol activities) Rockville Centre New York 11553 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05307939, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2026 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05307939 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →